How to Embrace a Data-Centric Approach to Make the Most of Protein Structure?
Pharma and biotech organizations are reaching the point where traditional processes (e.g. storing information in a scattered way) and legacy applications are not enough to handle the explosive scientific data, including protein structures.
At the same time, the adoption of protein therapeutics and technological advancements in the structural biology field continue to rise (see Nature’s 7 technologies to watch in 2022). For instance, Alpha FoldDB will produce 700 times more protein structures than currently in the PDB (around 186.000 entries) in the near future, which makes current big structural data gigantic.
Example of biomolecular data expansion - increase of PDB structures released per year https://www.rcsb.org/stats/growth/growth-released-structures
Such a trend imposes challenges in efficient structural data management which, if not addressed now, will have an adverse impact on the progress of the drug design projects in the future.
Centralize to Innovate
To turn the 700-fold data increase into 700 times more opportunities for new compound discovery, the first step is to bring scattered structural data to life, easily finable and accessible to all research units, at any time.
3decision® is Discngine’s modern software solution that centralizes an abundant amount of structural data (proteins, antibodies, homology models, etc.) into one single platform which allows pharma and biotech businesses to respond quickly to structural data avalanche and leverage science.
The Data-Centric Core of 3decision Embraces Innovation in Pharma and Biotech by:
Storing, standardizing, and analyzing the wealth of biological information from multiple locations into a single system for more efficiency and better data-driven drug discovery.
Democratizing the data within different teams involved in drug design projects (e.g. structural biologists and medicinal chemists) to ultimately drive teamwork and ideation.
Ensuring the right path for the new compound discovery by reducing risks of missing information, which can be unnecessarily time- and cost-consuming.
The empowerment of data-driven decision-making in pharma R&D to speed up the development of next-generation drugs is our mission at Discngine. Over 15 years Discngine has been developing effective digital solutions to streamline the early drug design processes and accelerate drug discovery.
Our Mission
Discngine is a Winner of 2019 Bio-IT World Innovative Practices Awards together with Abbvie for the co-development of 3decision®
“We were sitting on these almost 9,000 structures, and except for 2-3 people, nobody else knew where they were.”
- Rishi Gupta, Senior Research Scientist at Abbvie
“The 3decision® site has become a key stopping point for our scientists who design compounds, analyze and share protein structures, and retrieve external and internal protein x-ray and NMR structures.”
- Research Fellow, Discovery Chemistry at Abbvie